Barclays’s TriSalus Life Sciences TLSI Stock Holding History

Barclays’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.3K	Buy	8,647 +2,906	+51%	+$11.5K	﹤0.01%	4394
2026 Q1	$23K	Sell	5,741 -41,958	-88%	-$205K	﹤0.01%	4553
2025 Q4	$333K	Buy	47,699 +21,231	+80%	+$119K	﹤0.01%	4078
2025 Q3	$123K	Sell	26,468 -3,469	-12%	-$16.2K	﹤0.01%	4552
2025 Q2	$163K	Buy	29,937 +29,905	+93,453%	+$160K	﹤0.01%	4387
2025 Q1	$177	Buy	+32	New	+$170	﹤0.01%	5119
2022 Q4	–	Sell	-296,422	Closed	-$2.94M	–	5371
2022 Q3	$2.94M	Buy	296,422 +94,012	+46%	+$930K	﹤0.01%	1489
2022 Q2	$1.99M	Buy	202,410 +194,264	+2,385%	+$1.91M	﹤0.01%	1852
2022 Q1	$80K	Buy	+8,146	New	+$80.4K	﹤0.01%	3895

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Barclays's TLSI Position: Q2 2026 in Review

Barclays increased its TriSalus Life Sciences (TLSI) stake by 51% in Q2 2026, buying an estimated $11.5K and bringing the position to 8,647 shares worth $39.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4394.

Barclays first reported a position in TLSI in Q1 2022 and has held it in 9 quarters since. The position peaked at $2.94M in Q3 2022. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

Barclays held 8,647 shares of TriSalus Life Sciences worth $39.3K as of Q2 2026.
Barclays bought 2,906 TriSalus Life Sciences shares in Q2 2026, an estimated $11.5K.
TriSalus Life Sciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4394 holding.
Barclays first reported a position in TriSalus Life Sciences in Q1 2022 and has held it in 9 quarters since.
Barclays's TriSalus Life Sciences position peaked at $2.94M in Q3 2022.
79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.